Literature DB >> 34138421

Intravenously Infused Stem Cells for Cancer Treatment.

Alison R Mercer-Smith1, Ingrid A Findlay1, Hunter N Bomba1, Shawn D Hingtgen2,3.   

Abstract

Despite the recent influx of immunotherapies and small molecule drugs to treat tumors, cancer remains a leading cause of death in the United States, in large part due to the difficulties of treating metastatic cancer. Stem cells, which are inherently tumoritropic, provide a useful drug delivery vehicle to target both primary and metastatic tumors. Intravenous infusions of stem cells carrying or secreting therapeutic payloads show significant promise in the treatment of cancer. Stem cells may be engineered to secrete cytotoxic products, loaded with oncolytic viruses or nanoparticles containing small molecule drugs, or conjugated with immunotherapies. Herein we describe these preclinical and clinical studies, discuss the distribution and migration of stem cells following intravenous infusion, and examine both the limitations of and the methods to improve the migration and therapeutic efficacy of tumoritropic, therapeutic stem cells.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cell-based drug delivery; Intravenous therapy; Mesenchymal stem cells; Nanoparticle-loaded cells; Neural stem cells; Oncolytic viruses

Mesh:

Year:  2021        PMID: 34138421      PMCID: PMC8602714          DOI: 10.1007/s12015-021-10192-0

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  113 in total

1.  Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy.

Authors:  Chao Song; Juanjuan Xiang; Jingqun Tang; David G Hirst; Junwei Zhou; Kai-Ming Chan; Gang Li
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

Review 2.  Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy.

Authors:  Shen Cheng; Susheel Kumar Nethi; Sneha Rathi; Buddhadev Layek; Swayam Prabha
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

Review 3.  Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic.

Authors:  Hong-Hui Wu; Yi Zhou; Yasuhiko Tabata; Jian-Qing Gao
Journal:  J Control Release       Date:  2018-12-13       Impact factor: 9.776

4.  A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis.

Authors:  Xumei Ouyang; Xiaoling Wang; Heinz-Bernhard Kraatz; Soha Ahmadi; Jianqing Gao; Yuanyuan Lv; Xiaoyi Sun; Yongzhuo Huang
Journal:  Biomater Sci       Date:  2019-12-18       Impact factor: 6.843

5.  Epidemiology of liver metastases.

Authors:  Samantha R Horn; Kelsey C Stoltzfus; Eric J Lehrer; Laura A Dawson; Leila Tchelebi; Niraj J Gusani; Navesh K Sharma; Hanbo Chen; Daniel M Trifiletti; Nicholas G Zaorsky
Journal:  Cancer Epidemiol       Date:  2020-06-17       Impact factor: 2.984

Review 6.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

7.  Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.

Authors:  Lucia Kucerova; Miroslava Matuskova; Andrea Pastorakova; Silvia Tyciakova; Jana Jakubikova; Roman Bohovic; Veronika Altanerova; Cestmir Altaner
Journal:  J Gene Med       Date:  2008-10       Impact factor: 4.565

Review 8.  Stem cell-based therapies for cancer treatment: separating hope from hype.

Authors:  Daniel W Stuckey; Khalid Shah
Journal:  Nat Rev Cancer       Date:  2014-09-01       Impact factor: 60.716

9.  Systemically Infused Mesenchymal Stem Cells Show Different Homing Profiles in Healthy and Tumor Mouse Models.

Authors:  Chengying Xie; Zhangru Yang; Yuanzhen Suo; Qianqian Chen; Dan Wei; Xiaofu Weng; Zhengqin Gu; Xunbin Wei
Journal:  Stem Cells Transl Med       Date:  2017-02-16       Impact factor: 6.940

10.  Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2.

Authors:  Hong Lei; Aqu Alu; Jingyun Yang; Cai He; Weiqi Hong; Zesheng Cheng; Li Yang; Jiong Li; Zhenling Wang; Wei Wang; Guangwen Lu; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2020-12-11
View more
  1 in total

Review 1.  Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.

Authors:  Aadya Nayak; Neerada Meenakshi Warrier; Praveen Kumar
Journal:  Stem Cell Rev Rep       Date:  2022-07-25       Impact factor: 6.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.